Download PDF
Z Gastroenterol 2004; 42(10): 1189-1198
DOI: 10.1055/s-2004-812927
Übersicht

© Karl Demeter Verlag im Georg Thieme Verlag Stuttgart · New York

Chemotherapie kolorektaler Karzinome im Alter

Chemotherapy for Colorectal Carcinoma in the ElderlyV. Kächele1 , P. Hahn1 , G. Adler1 , T. Seufferlein1
  • 1Abteilung Innere Medizin I, Universitätsklinikum Ulm
Further Information

Publication History

Manuskript eingetroffen: 21.1.2004

Manuskript akzeptiert: 28.1.2004

Publication Date:
27 October 2004 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Das kolorektale Karzinom ist mit einem mittleren Erkrankungsalter von knapp 70 Jahren überwiegend eine Erkrankung des höheren Lebensalters. Aus vorliegenden Studien zur Chemotherapie des kolorektalen Karzinoms zeigt sich, dass auch ältere Patienten sowohl von einer adjuvanten als auch palliativen zytostatischen Therapie profitieren. Im Vergleich zu jüngeren Patienten ist bei älteren Patienten in gutem Allgemeinzustand bei ähnlichem Therapieansprechen eine nur geringgradig erhöhte Toxizität zu erwarten.

Ältere Patienten sind in klinischen Studien deutlich unterrepräsentiert. Daher können die vorliegenden Daten nicht generell auf ältere Patienten mit kolorektalem Karzinom bezogen werden. Durch geriatrisches Assessment können therapierelevante Informationen zur besseren Patientenselektion erzielt werden. Auf der Grundlage eines solchen Assessments sollte bei der Vielzahl neuerer Medikamente, die derzeit in die Therapie des kolorektalen Karzinoms integriert werden, Wert darauf gelegt werden, geeignete ältere Patienten auch in klinischen Studien zu behandeln.

Abstract

With nearly 50 % of all colorectal cancers being diagnosed in patients at the age of 70 or above colorectal cancer is a disease of the elderly. In an adjuvant setting, fit elderly patients can receive the same benefit from cytotoxic therapy as younger patients with an only slightly increased toxicity.

In a palliative setting, the treatment of elderly patients with respect to clinical endpoints such as response, time to progression or overall survival is as effective as in their younger counterparts. In clinical studies, older patients are generally underrepresented and among the elderly patients involved in clinical studies there is a bias towards particularly fit patients. Therefore it is not possible to extrapolate the results of many randomized trials to all elderly patients. A Comprehensive Geriatric Assessment (CGA) should be applied to detect the diversities in the geriatric population. Based on this assessment elderly patients classified as suitable for chemotherapy should be enrolled into clinical trials for colorectal cancer.

Schlüsselwörter

Kolorektales Karzinom - Chemotherapie - Geriatrische Onkologie

Key words

colorectal cancer - chemotherapy - geriatric oncology

Literatur

  • 1 Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland. Krebs in Deutschland - Häufigkeiten und Trends. 3. erw. aktual. Auflage Saarbrücken; 2002: 28-31
    Google Scholar
  • 2 Levi F, Lucchini F, Negri E. et al . Mortality from major cancer sites in the European Union, 1955 - 1998.  Ann Oncol. 2003;  14 490-495
    CrossrefPubMedGoogle Scholar
  • 3 Yancik R. Cancer burden in the aged. An epidemiologic and demographic overview.  Cancer. 1997;  80 1273-1283
    CrossrefPubMedGoogle Scholar
  • 4 Coiffier B, Lepage E, Briere J. et al . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.  N Engl J Med. 2002;  346 235-242
    CrossrefPubMedGoogle Scholar
  • 5 Schild S E, Stella P J, Geyer S M. et al . The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly.  J Clin Oncol. 2003;  21 3201-3206
    CrossrefPubMedGoogle Scholar
  • 6 Bouchardy C, Rapiti E, Fioretta G. et al . Undertreatment strongly decreases prognosis of breast cancer in elderly women.  J Clin Oncol. 2003;  21 3580-3587
    CrossrefPubMedGoogle Scholar
  • 7 Honecker F, Köhne C H, Bokemeyer C. Colorectal cancer in the elderly. Is palliative chemotherapy of value?.  Drugs Aging. 2003;  20 1-11
    PubMedGoogle Scholar
  • 8 Trimble E L, Carter C L, Cain D. et al . Representation of older patients in cancer treatment trials.  Cancer. 1994;  74 2208-2214
    PubMedGoogle Scholar
  • 9 Hutchins L F, Unger J M, Crowley J J. et al . Underrepresentation of patients 65 years of age and older in cancer treatment trials.  N Engl J Med. 1999;  341 2061-2067
    CrossrefPubMedGoogle Scholar
  • 10 Lewis J H, Kilgore M L, Goldman. et al . Participation of patients 65 years of age or older in cancer clinical trials.  J Clin Oncol. 2003;  21 1383-1389
    CrossrefPubMedGoogle Scholar
  • 11 Monfardini S, Sorio R, Boes G H. et al . Entry and evaluation of elderly patients in European Organisation for Research and Treatment of Cancer (EORTC) new drug-development studies.  Cancer. 1995;  76 333-338
    PubMedGoogle Scholar
  • 12 Yee K WL, Pater J L, Pho L. et al . Enrollment of older patients in cancer treatment trials: Why is age a barrier?.  J Clin Oncol. 2003;  21 1618-1623
    CrossrefPubMedGoogle Scholar
  • 13 Ogle K S, Swanson G M, Woods N. et al . Cancer and comorbidity. Redefining chronic diseases.  Cancer. 2000;  88 653-663
    CrossrefPubMedGoogle Scholar
  • 14 Yancik R, Wesley M N, Ries R AG. et al . Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients.  Cancer. 1998;  82 2123-2134
    CrossrefPubMedGoogle Scholar
  • 15 Charlson M E, Pompei P, Ales K. et al . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.  J Chron Dis. 1987;  40 373-383
    CrossrefPubMedGoogle Scholar
  • 16 Extermann M. Measuring comorbidity in older cancer patients.  Eur J Cancer. 2000;  36 453-471
    CrossrefPubMedGoogle Scholar
  • 17 Nikolaus T. Geriatrisches Assessment. Nikolaus T Klinische Geriatrie Berlin; Springer Verlag 2000: 159-188
    Google Scholar
  • 18 Repetto L, Fratino L, Audisio R A. et al . Comprehensive Geriatric Assessment adds information to Eastern Cooperative Oncology Group Performance Status in elderly cancer patients: An Italian Group for Geriatric Oncology Study.  J Clin Oncol. 2002;  20 494-502
    CrossrefPubMedGoogle Scholar
  • 19 Balducci L, Exterman M. Management of Cancer in the older person: a practical approach.  The Oncologist. 2000;  5 224-237
    CrossrefPubMedGoogle Scholar
  • 20 Friedrich C, Kolb G, Wedding U. et al . Comprehensive geriatric assessment in the elderly cancer patient.  Onkologie. 2003;  26 355-360
    CrossrefPubMedGoogle Scholar
  • 21 Balducci L, Stanta G. Cancer in the frail patient: a coming epidemic.  Hematol Oncol Clin North Am. 2000;  14 235-250
    CrossrefPubMedGoogle Scholar
  • 22 Kaufman D W, Kelly J P, Rosenberg L. et al . Recent pattern of medication use in the ambulatory adult population of the United States: the Slone Survey.  JAMA. 2002;  287 337-344
    Google Scholar
  • 23 Kimmick G G, Fleming R, Muss H B. et al . Cancer chemotherapy in older adults. A tolerability perspective.  Drugs Aging. 1997;  10 34-49
    PubMedGoogle Scholar
  • 24 Mathijssen R H, Verweij J, de Bruijn P. et al . Effects of St.John’s wort on irinotecan metabolism.  J Natl Cancer Inst. 2002;  94 1247-1249
    CrossrefPubMedGoogle Scholar
  • 25 Vestal R E. Aging and pharmacology.  Cancer. 1997;  80 1302-1310
    CrossrefPubMedGoogle Scholar
  • 26 Saltz L B, Cox J V, Blanke C. et al . Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.  N Engl J Med. 2000;  343 905-914
    CrossrefPubMedGoogle Scholar
  • 27 Douillard J Y, Cunnungham D, Roth A D. et al . Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial.  Lancet. 2000;  355 1041-1047
    CrossrefPubMedGoogle Scholar
  • 28 Giacchetti S, Perpoint B, Zidani R. et al . Phase III multicenter trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.  J Clin Oncol. 2000;  18 136-47
    PubMedGoogle Scholar
  • 29 De Gramont A, Figer A, Seymour M. et al . Leukovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.  J Clin Oncol. 2000;  18 2938-47
    CrossrefPubMedGoogle Scholar
  • 30 Koehne C H, Van Cutsem E, Wils J A. Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: Results of EORTC GI Group study 40 986.  Proc Am Soc Clin Oncol. 2003;  22 1017 (Abstract)
    PubMedGoogle Scholar
  • 31 Hurwitz H, Fehrenbacher L, Cartwright T. et al . Bevacizumab prolongs survival in first-line colorectal cancer: Results of a phase III trial of bevacizumab in combination with bolus IFL as a first-line therapy in subjects with metastatic CRC.  Proc Am Soc Clin Oncol. 2003;  22 3646 (Abstract)
    PubMedGoogle Scholar
  • 32 Cunningham D, Humblet Y, Siena S. et al . Cetuximab (C225) alone or in combination with irinotecan in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC).  Proc Am Soc Clin Oncol. 2003;  22 1012 (Abstract)
    PubMedGoogle Scholar
  • 33 Colorectal Cancer Collaborative Group . Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis.  BMJ. 2000;  321 531-535
    CrossrefPubMedGoogle Scholar
  • 34 Meta-Analysis Group in Cancer . Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.  J Clin Oncol. 1998;  16 3537-3541
    PubMedGoogle Scholar
  • 35 Köhne C H, Cunningham D, Di Constanzo F. et al . Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 Patients.  Ann Oncol. 2002;  13 308-317
    CrossrefPubMedGoogle Scholar
  • 36 Vanhöfer U, Köhne C H. Chemotherapeutische Möglichkeiten bei metastasiertem kolorektalen Karzinom.  Dtsch Ärzteblatt. 2003;  100 705-714
    PubMedGoogle Scholar
  • 37 Diasio R B, Harris B E. Clinical pharmacology of 5-fluorouracil.  Clin Pharmacokinet. 1989;  16 215-237
    PubMedGoogle Scholar
  • 38 Bokemeyer C, Perry M C. Kompendium Internistische Onkologie, Teil 1. Schmoll HJ, Höffken K, Possinger K Berlin; Springer 1999: 1404
    Google Scholar
  • 39 Sloan J A, Goldberg R M, Sargent D J. et al . Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer.  J Clin Oncol. 2002;  20 1491-1498
    PubMedGoogle Scholar
  • 40 Becker K, Erckenbrecht J F, Häussinger D. et al . Cardiotoxicity of the antiproliferative compound fluorouracil.  Drugs. 1999;  57 475-484
    PubMedGoogle Scholar
  • 41 Robben N C, Pippas A W, Moore J O. The syndrome of 5-fluorouracil cardiotoxicity: an elusive cardiopathy.  Cancer. 1993;  71 493-509
    PubMedGoogle Scholar
  • 42 Raida M, Schwabe W, Häusler P. et al . Prevalence of a common point mutation in the Dihydropyrimidine Dehydrogenase (DPD) Gene with the 5‘-Splice Donor Site of Intron 14 in patients with severe 5-Fluorouracil (5-FU)-related toxicity compared with controls.  Clin Cancer Res. 2001;  7 2832-2839
    PubMedGoogle Scholar
  • 43 Van Kuilenburg A BP, Haasjes J, Richel D. et al . Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-Fluorouracil-associated toxicity: identification of new mutations in the DPD gene.  Clin Cancer Res. 2000;  6 4705-4712
    PubMedGoogle Scholar
  • 44 Van Kuilenburg A BP, Muller E W, Haasjes J. et al . Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14 + 1GA mutation causing DPD-deficiency.  Clin Cancer Res. 2001;  7 1149-1153
    PubMedGoogle Scholar
  • 45 Köhne C H, Wils J, Lorenz M. et al . Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leukovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European Organisation of Research and treatment of Cancer Gastrointestinal Group Study 40 952.  J Clin Oncol. 2003;  21 3721-3728
    CrossrefPubMedGoogle Scholar
  • 46 Stein B N, Petrelli N J, Douglass H O. et al . Age and sex are independent predictors of 5-fluorouracil toxicity.  Cancer. 1995;  75 11-17
    CrossrefPubMedGoogle Scholar
  • 47 Zalcberg J, Kerr D, Seymour L. et al . Haematological and Non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number.  Eur J Cancer. 1998;  34 1871-1875
    CrossrefPubMedGoogle Scholar
  • 48 Chiara S, Nobile M T, Vincenti M. et al . Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy.  Cancer Chemother Pharmacol. 1998;  42 336-340
    CrossrefPubMedGoogle Scholar
  • 49 Daniele B, Rosati G, Pignata S. et al . Phase II study of first line chemotherapy with de Gramont schedule for elderly patients with advanced colorectal cancer.  Proc Am Soc Clin Oncol. 2002;  21 2243 (Abstract)
    PubMedGoogle Scholar
  • 50 Popescu R A, Norman A, Ross P J. et al . Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older.  J Clin Oncol. 1999;  17 2412-2418
    PubMedGoogle Scholar
  • 51 Jacobson S D, Cha S, Sargent D J. et al . Tolerability, dose intensity, and benefit of 5-FU-based chemotherapy for advanced colorectal cancer (CRC) in the elderly. A North Central Cancer Treatment Group (NCCTG) Study.  Proc Am Soc Clin Oncol. 2001;  20 1534 (Abstract)
    PubMedGoogle Scholar
  • 52 Magne N, Francois E, Broisin L. et al . Palliative 5-fluorouracil-based chemotherapy for advanced colorectal cancer in the elderly: results of a 10-years experience.  Am J Clin Oncol. 2002;  25 126-130
    CrossrefPubMedGoogle Scholar
  • 53 O’Conell M J, Martenson J A, Wieand H S. et al . Improving adjuvant therapy for rectal cancer by combining protracted infusion fluorouracil with radiation therapy after curative surgery.  N Engl J Med. 1994;  331 502-507
    CrossrefPubMedGoogle Scholar
  • 54 Neugut A I, Fleischauer A T, Sundararajan V. et al . Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: A population-based study.  J Clin Oncol. 2002;  20 2643-2650
    CrossrefPubMedGoogle Scholar
  • 55 Janjan N A, Khoo V S, Abbruzzese J. et al . Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: The M.D. Anderson Cancer Center experience.  Int J Radiat Oncol Biol Phys. 1999;  44 1027-1038
    CrossrefPubMedGoogle Scholar
  • 56 Rödel C, Grabenbauer G G, Papadopoulos T. et al . Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer.  J Clin Oncol. 2003;  21 3098-3104
    CrossrefPubMedGoogle Scholar
  • 57 Schrag D S, Cramer L D, Bach P B. et al . Age and adjuvant chemotherapy use after surgery for stage III colon cancer.  J Natl Cancer Inst. 2001;  93 850-857
    CrossrefPubMedGoogle Scholar
  • 58 Sargent D J, Goldberg R M, Jacobson S D. et al . A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.  N Engl J Med. 2001;  345 1091-1097
    CrossrefPubMedGoogle Scholar
  • 59 Iwashyna T J, Lamont E B. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer.  J Clin Oncol. 2002;  20 3992-3998
    CrossrefPubMedGoogle Scholar
  • 60 Tabah-Fisch I, Maindrault-Goebel F, Benavides M. et al . Oxaliplatin is feasible, safe and active in elderly colorectal cancer (CRC) patients.  Proc Am Soc Clin Oncol. 2002;  21 556 (Abstract)
    PubMedGoogle Scholar
  • 61 Borner M, Schöffski P, de Wit R. et al . Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.  Eur J Cancer. 2002;  38 349-358
    CrossrefPubMedGoogle Scholar
  • 62 Twelves C. Capecitabine as first-line treatment in colorectal cancer; pooled data from two large, phase III trials.  Eur J Cancer. 2002;  38 (Suppl. 2) 15-20
    PubMedGoogle Scholar
  • 63 Cassidy J, Twelves C, Van Cutsem E. et al . First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.  Ann Oncol. 2002;  13 566-575
    CrossrefPubMedGoogle Scholar
  • 64 Escudero P, Verge V, Feliu J. et al . A study of capecitabine in elderly patients as first line treatment in advanced or metastatic colorectal cancer.  Proc Am Soc Clin Oncol. 2003;  22 3114 (Abstract)
    PubMedGoogle Scholar
  • 65 Diaz-Rubio E, Sastrre J, Abad A. et al . UFT plus or minus calcium folinate for metastatic colorectal cancer in older patients.  Oncology. 1999;  13 35-40
    PubMedGoogle Scholar
  • 66 Feliu J, Gonzalez B aron M, Espinosa E. et al . Uracil and tegafur modulated with leucovorin. An effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly.  Cancer. 1997;  79 1884-1889
    CrossrefPubMedGoogle Scholar
  • 67 Cily C R, Clemett D, Wisemann L R. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.  Drugs. 2000;  60 895-924
    PubMedGoogle Scholar
  • 68 Takimoto C H, Remick S C, Sharma S. et al . Dose-escalating and pharmacological study of Oxaliplatin in adult cancer patients with impaired renal function: A National Cancer Institute Organ Dysfunction Working Group Study.  J Clin Oncol. 2003;  21 2664-2672
    CrossrefPubMedGoogle Scholar
  • 69 Martin G, Graham L, Cunningham D. et al . Pharmacokinetics of Oxaliplatin in special populations. (Abstract).  Proc Am Soc Clin Oncol. 1999;  18 729
    PubMedGoogle Scholar
  • 70 Eckel F, Schmelz R, Adelsberger H. et al . Prophylaxe der Oxaliplatin-induzierten Neuropathie mit Carbamazepin.  DMW. 2002;  127 78-82
    PubMedGoogle Scholar
  • 71 Levi F, Zidani R, Focan C. et al . Age-independent benefit of chronotherapy with 5-fluorouracil, leucovorin and oxaliplatin in patients with metastatic colorectal cancer within multicenter randomized phase III trials.  Proc Am Soc Clin Oncol. 2002;  21 1431 (Abstract)
    PubMedGoogle Scholar
  • 72 Mattioli R, Reccchia F, Lippe P. et al . Bi-fractionated “folfox” as first line chemotherapy (CT) in elderly patients with metastatic colorectal cancer.  Proc Am Soc Clin Oncol. 2003;  22 1411 (Abstract)
    PubMedGoogle Scholar
  • 73 De Gramont A, Banzi M, Navarro M. et al . Oxaliplatin/5-FU/LV in adjuvant colon cancer: Results of the international randomized mosaic trial.  Proc Am Soc Clin Oncol. 2003;  22 1015 (Abstract)
    PubMedGoogle Scholar
  • 74 Pizzolato J F, Saltz L B. The camptothecins.  Lancet. 2003;  361 2235-2242
    CrossrefPubMedGoogle Scholar
  • 75 Schaaf L, Ichhpurani N, Elfring G. et al . Influence of age on the pharmacokinetics of irinotecan (CPT-11) and its metabolites, SN-38 and SN-38 glucuronide (SN-38G), in patients with previously treated colorectal cancer.  Proc Am Soc Clin Oncol. 1997;  16 (Abstract)
    PubMedGoogle Scholar
  • 76 Stemmler J, Weise A, Hacker U. et al . Weekly Irinotecan in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure.  Onkologie. 2002;  25 60-63
    PubMedGoogle Scholar
  • 77 Rothenberg M L, Meropol N J, Poplin E A. et al . Mortality associated with irinotecan plus bolus Fluorouracil/leucovorin: summary findings of an independent panel.  J Clin Oncol. 2001;  19 3801-3807
    PubMedGoogle Scholar
  • 78 Wang E, Anderson S E, Hummer A. et al . Dose intensity and toxicity of CPT-11 in geriatric metastatic colorectal cancer patients.  Proc Am Soc Clin Oncol. 2002;  21 1448 (Abstract)
    PubMedGoogle Scholar
  • 79 Rothenberg M L, Cox J V, DeVore R F. et al . A multicenter, phase II trial of weekly Irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.  Cancer. 1999;  85 786-795
    CrossrefPubMedGoogle Scholar
  • 80 Rougier P, Mitry E, Cunningham D. et al . Is age a prognostic factor of toxicity in patients with metastatic colorectal cancer receiving irinotecan in combination with 5-FU/folinic acid.  Proc Am Soc Clin Oncol. 2003;  22 1072 (Abstract)
    PubMedGoogle Scholar

Dr. V. Kächele

Abt. Innere Medizin I, Universitätsklinikum Ulm

Robert-Koch-Straße 8

89081 Ulm

      >